Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

ProAxsis signs partnership with a large US based biotechnology company

ProAxsis
Posted on: 12 Sep 17

ProAxsis Ltd today announces that the company has signed a partnership agreement to develop activity-based immunoassays for two key respiratory proteases, utilising its ProteaseTag® technology.  The partner is a large biotechnology company, with headquarters in the US, and a focus on developing new therapeutic options for patients with rare diseases.

ProAxsis’ ProteaseTag® technology enables the specific and sensitive detection and measurement of the active form of proteases, which represent strong therapeutic targets in a number of different diseases.  Early work has focused on neutrophil elastase, as a biomarker of lung infection and inflammation, but the platform technology potentially allows any protease to be targeted.

Dr David Ribeiro, CEO of ProAxsis, said, “A key part of our strategy for ProAxsis is to identify and form collaborations with biotechnology companies who are developing therapeutics where a protease is a key target or offers a valuable endpoint.  We’re therefore delighted to have reached this agreement, and look forward to providing our partner with some useful tools for their ongoing clinical trial work.”

To find out how ProAxsis can support the measurement of active protease biomarkers of disease, or for any further queries, please contact info@proaxsis.com

 

About NetScientific

 

NetScientific is a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases. For more information, please visit the website at www.netscientific.net

 

About ProAxsis Limited:

 

ProAxsis is developing a range of products for the capture, detection and measurement of active protease biomarkers of diseases. Its first immunoassay measures neutrophil elastase, a leading indicator of infection and inflammation in patients with Cystic Fibrosis (CF), Chronic Obstructive Pulmonary Disease (COPD) and bronchiectasis, and an important drug target. The rapid and easy-to-use tests being developed by ProAxsis incorporate patented ProteaseTags®; smart molecules which trap an active protease within a complex biological sample and enable a visual readout of its presence. ProteaseTags® provide a unique tool to identify and quantify active protease biomarkers and will assist in the clinical validation of new therapeutics.

ProAxsis is part of the NetScientific Group and is one of the Group’s core portfolio companies.  The company is also supported by QUBIS, the commercialisation arm of Queens University.

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 12/09/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.